- Home
- USEG vs OPTN Comparison
USEG vs OPTN Comparison
Compare USEG & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEG
- OPTN
- Stock Information
- Founded
- USEG 1966
- OPTN 2010
- Country
- USEG United States
- OPTN United States
- Employees
- USEG N/A
- OPTN N/A
- Industry
- USEG Oil & Gas Production
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- USEG Energy
- OPTN Health Care
- Exchange
- USEG Nasdaq
- OPTN Nasdaq
- Market Cap
- USEG 68.6M
- OPTN 55.4M
- IPO Year
- USEG N/A
- OPTN 2017
- Fundamental
- Price
- USEG $1.95
- OPTN $5.77
- Analyst Decision
- USEG Strong Buy
- OPTN Strong Buy
- Analyst Count
- USEG 2
- OPTN 3
- Target Price
- USEG $2.75
- OPTN $16.67
- AVG Volume (30 Days)
- USEG 4.2M
- OPTN 18.9K
- Earning Date
- USEG 03-25-2025
- OPTN 03-06-2025
- Dividend Yield
- USEG N/A
- OPTN N/A
- EPS Growth
- USEG N/A
- OPTN N/A
- EPS
- USEG N/A
- OPTN N/A
- Revenue
- USEG $22,257,000.00
- OPTN $75,672,000.00
- Revenue This Year
- USEG N/A
- OPTN $13.42
- Revenue Next Year
- USEG $12.17
- OPTN $38.54
- P/E Ratio
- USEG N/A
- OPTN N/A
- Revenue Growth
- USEG N/A
- OPTN 5.13
- 52 Week Low
- USEG $0.81
- OPTN $4.82
- 52 Week High
- USEG $6.40
- OPTN $31.50
- Technical
- Relative Strength Index (RSI)
- USEG 43.97
- OPTN 44.78
- Support Level
- USEG $2.03
- OPTN $5.20
- Resistance Level
- USEG $2.17
- OPTN $6.49
- Average True Range (ATR)
- USEG 0.22
- OPTN 0.50
- MACD
- USEG -0.05
- OPTN 0.04
- Stochastic Oscillator
- USEG 0.00
- OPTN 44.19
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business activities in South Texas and the Williston Basin in North Dakota. The company generates revenue from its interest in the sales of oil and natural gas production.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.